{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:07:38Z","timestamp":1785424058924,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["GM131729"],"award-info":[{"award-number":["GM131729"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["GT12053"],"award-info":[{"award-number":["GT12053"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HATFUL19GO"],"award-info":[{"award-number":["HATFUL19GO"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nontuberculous mycobacterium (NTM) infections are challenging to manage and are frequently non-responsive to aggressive but poorly-tolerated antibiotic therapies. Immunosuppressed lung transplant patients are susceptible to NTM infections and poor patient outcomes are common. Bacteriophages present an alternative treatment option and are associated with favorable clinical outcomes. Similarly, dual beta-lactam combinations show promise in vitro, but clinical use is sparse. We report here a patient with an uncontrolled <jats:italic>Mycobacterium abscessus<\/jats:italic> infection following a bilateral lung transplant and failed antibiotic therapy. Both smooth and rough colony morphotype strains were initially present, but treatment with two phages that kill the rough strain \u2013 including epigenetic-modification to overcome restriction \u2013 resulted in isolation of only the smooth strain. The rough and smooth strains have similar antibiotic susceptibilities suggesting that the phages specifically eliminated the rough strain. Dual beta-lactam therapy with meropenem and ceftazidime-avibactam provided further clinical improvement, and the phages act synergistically with meropenem in vitro.<\/jats:p>","DOI":"10.1038\/s41467-024-54666-4","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T17:51:45Z","timestamp":1732816305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Use of epigenetically modified bacteriophage and dual beta-lactams to treat a Mycobacterium abscessus sternal wound infection"],"prefix":"10.1038","volume":"15","author":[{"given":"Madison","family":"Cristinziano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Shashkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5845-2235","authenticated-orcid":false,"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa B.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Doligalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Coakley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard Jason","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Footer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7596-4272","authenticated-orcid":false,"given":"Luther","family":"Bartelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Garlena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6118-1429","authenticated-orcid":false,"given":"Michael J.","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Viland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Kaganovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Mowry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7838-3257","authenticated-orcid":false,"given":"Deborah","family":"Jacobs-Sera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"van Duin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-131X","authenticated-orcid":false,"given":"Barry N.","family":"Kreiswirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6705-6821","authenticated-orcid":false,"given":"Graham F.","family":"Hatfull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Friedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"54666_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/ajt.12101","volume":"13","author":"MR Keating","year":"2013","unstructured":"Keating, M. R., Daly, J. S. & Practice ASTIDCo. Nontuberculous mycobacterial infections in solid organ transplantation. Am. J. Transpl. 13, 77\u201382 (2013).","journal-title":"Am. J. Transpl."},{"key":"54666_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13588","volume":"33","author":"SA Longworth","year":"2019","unstructured":"Longworth, S. A. & Daly, J. S. Practice ASTIDCo. Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin. Transpl. 33, e13588 (2019).","journal-title":"Clin. Transpl."},{"key":"54666_CR3","doi-asserted-by":"crossref","unstructured":"Osman, L. et al. Therapy of Mycobacterium abscessus infections in solid organ transplant patients. Microorganisms 12, 596 (2024).","DOI":"10.3390\/microorganisms12030596"},{"key":"54666_CR4","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1513\/AnnalsATS.201804-236OC","volume":"17","author":"KL Winthrop","year":"2020","unstructured":"Winthrop, K. L. et al. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008-2015. Ann. Am. Thorac. Soc. 17, 178\u2013185 (2020).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"54666_CR5","doi-asserted-by":"crossref","unstructured":"Novosad, S. A., Beekmann, S. E., Polgreen, P. M., Mackey, K., Winthrop, K. L. & Team MaS. Treatment of Mycobacterium abscessus infection. Emerg. Infect. Dis. 22, 511\u2013514 (2016).","DOI":"10.3201\/eid2203.150828"},{"key":"54666_CR6","doi-asserted-by":"crossref","unstructured":"Degiacomi, G. et al. Mycobacterium abscessus, an emerging and worrisome pathogen among cystic fibrosis patients. Int. J. Mol. Sci. 20, 5868 (2019).","DOI":"10.3390\/ijms20235868"},{"key":"54666_CR7","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.cmi.2023.08.036","volume":"30","author":"M Lagune","year":"2024","unstructured":"Lagune, M., Kremer, L. & Herrmann, J. L. Mycobacterium abscessus, a complex of three fast-growing subspecies sharing virulence traits with slow-growing mycobacteria. Clin. Microbiol. Infect. 30, 726\u2013731 (2024).","journal-title":"Clin. Microbiol. Infect."},{"key":"54666_CR8","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3201\/2109.141634","volume":"21","author":"MR Lee","year":"2015","unstructured":"Lee, M. R. et al. Mycobacterium abscessus complex infections in humans. Emerg. Infect. Dis. 21, 1638\u20131646 (2015).","journal-title":"Emerg. Infect. Dis."},{"key":"54666_CR9","doi-asserted-by":"publisher","first-page":"e81560","DOI":"10.1371\/journal.pone.0081560","volume":"8","author":"YJ Cho","year":"2013","unstructured":"Cho, Y. J. et al. The genome sequence of \u2018Mycobacterium massiliense\u2019 strain CIP 108297 suggests the independent taxonomic status of the Mycobacterium abscessus complex at the subspecies level. PLoS ONE 8, e81560 (2013).","journal-title":"PLoS ONE"},{"key":"54666_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-359","volume":"15","author":"M Sassi","year":"2014","unstructured":"Sassi, M. & Drancourt, M. Genome analysis reveals three genomospecies in Mycobacterium abscessus. BMC Genomics 15, 359 (2014).","journal-title":"BMC Genomics"},{"key":"54666_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jctube.2016.04.001","volume":"4","author":"CL Abad","year":"2016","unstructured":"Abad, C. L. & Razonable, R. R. Non-tuberculous mycobacterial infections in solid organ transplant recipients: an update. J. Clin. Tuberc. Other Mycobact. Dis. 4, 1\u20138 (2016).","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis."},{"key":"54666_CR12","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ajt.2023.04.009","volume":"23","author":"AE Friedland","year":"2023","unstructured":"Friedland, A. E. et al. Epidemiology, management, and clinical outcomes of extrapulmonary Mycobacterium abscessus complex infections in heart transplant and ventricular assist device recipients. Am. J. Transpl. 23, 1048\u20131057 (2023).","journal-title":"Am. J. Transpl."},{"key":"54666_CR13","doi-asserted-by":"crossref","unstructured":"Palucci I. & Delogu G. Alternative therapies against Mycobacterium abscessus infections. Clin. Microbiol. Infect. 30, 732\u2013737 (2023).","DOI":"10.1016\/j.cmi.2023.10.001"},{"key":"54666_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s41030-022-00210-y","volume":"9","author":"GF Hatfull","year":"2023","unstructured":"Hatfull, G. F. Phage therapy for nontuberculous mycobacteria: challenges and opportunities. Pulm. Ther. 9, 91\u2013107 (2023).","journal-title":"Pulm. Ther."},{"key":"54666_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/cid\/ciac453","volume":"76","author":"RM Dedrick","year":"2023","unstructured":"Dedrick, R. M. et al. Phage therapy of Mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease. Clin. Infect. Dis. 76, 103\u2013112 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"54666_CR16","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"RM Dedrick","year":"2019","unstructured":"Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730\u2013733 (2019).","journal-title":"Nat. Med."},{"key":"54666_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29689-4","volume":"13","author":"JS Little","year":"2022","unstructured":"Little, J. S. et al. Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection. Nat. Commun. 13, 2313 (2022).","journal-title":"Nat. Commun."},{"key":"54666_CR18","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.cell.2022.04.024","volume":"185","author":"JA Nick","year":"2022","unstructured":"Nick, J. A. et al. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell 185, 1860\u20131874.e1812 (2022).","journal-title":"Cell"},{"key":"54666_CR19","doi-asserted-by":"publisher","first-page":"1335 e1339","DOI":"10.1016\/j.cmi.2023.06.026","volume":"29","author":"RM Dedrick","year":"2023","unstructured":"Dedrick, R. M. et al. The problem of Mycobacterium abscessus complex: multi-drug resistance, bacteriophage susceptibility and potential healthcare transmission. Clin. Microbiol. Infect. 29, 1335 e1339\u20131335 e1316 (2023).","journal-title":"Clin. Microbiol. Infect."},{"key":"54666_CR20","doi-asserted-by":"crossref","unstructured":"Dedrick, R. M. et al. Mycobacterium abscessus strain morphotype determines phage susceptibility, the repertoire of therapeutically useful phages, and phage resistance. mBio 12, e03431-20 (2021).","DOI":"10.1128\/mBio.03431-20"},{"key":"54666_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","volume":"71","author":"CL Daley","year":"2020","unstructured":"Daley, C. L. et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Clin. Infect. Dis. 71, 905\u2013913 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"54666_CR22","doi-asserted-by":"crossref","unstructured":"Pandey, R. et al. Dual beta-lactam combinations highly active against Mycobacterium abscessus complex in vitro. mBio 10, e02895-18 (2019).","DOI":"10.1128\/mBio.02895-18"},{"key":"54666_CR23","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.cmi.2024.03.019","volume":"30","author":"M Pozuelo Torres","year":"2024","unstructured":"Pozuelo Torres, M. & van Ingen, J. Dual beta-lactam therapy to improve treatment outcome in Mycobacterium abscessus disease. Clin. Microbiol. Infect. 30, 738\u2013742 (2024).","journal-title":"Clin. Microbiol. Infect."},{"key":"54666_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad312","volume":"10","author":"B Alahmdi","year":"2023","unstructured":"Alahmdi, B. et al. Eradicating pulmonary Mycobacterium abscessus: the promise of dual beta-lactam therapy. Open Forum Infect. Dis. 10, ofad312 (2023).","journal-title":"Open Forum Infect. Dis."},{"key":"54666_CR25","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00319-24","volume":"68","author":"B Becken","year":"2024","unstructured":"Becken, B., Dousa, K. M., Johnson, J. L., Holland, S. M. & Bonomo, R. A. Dual beta-lactam for treatment of pulmonary Mycobacterium abscessus in a child. Antimicrob. Agents Chemother. 68, e0031924 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"54666_CR26","first-page":"e40993","volume":"15","author":"N Moguillansky","year":"2023","unstructured":"Moguillansky, N., DeSear, K. & Dousa, K. M. A 40-year-old female with Mycobacterium abscessus successfully treated with a dual beta-lactam combination. Cureus 15, e40993 (2023).","journal-title":"Cureus"},{"key":"54666_CR27","doi-asserted-by":"crossref","unstructured":"Dedrick, R. M. et al. The prophage and plasmid mobilome as a likely driver of Mycobacterium abscessus diversity. mBio 12, e03441-20 (2021).","DOI":"10.1128\/mBio.03441-20"},{"key":"54666_CR28","doi-asserted-by":"crossref","unstructured":"Abad, L., Gauthier, C. H., Florian, I., Jacobs-Sera, D. & Hatfull, G. F. The heterogenous and diverse population of prophages in Mycobacterium genomes. mSystems 8, e0044623 (2023).","DOI":"10.1128\/msystems.00446-23"},{"key":"54666_CR29","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nsmb.3064","volume":"22","author":"J Sun","year":"2015","unstructured":"Sun, J. et al. The tuberculosis necrotizing toxin kills macrophages by hydrolyzing NAD. Nat. Struct. Mol. Biol. 22, 672\u2013678 (2015).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"54666_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1146\/annurev-virology-122019-070009","volume":"7","author":"GF Hatfull","year":"2020","unstructured":"Hatfull, G. F. Actinobacteriophages: genomics, dynamics, and applications. Annu. Rev. Virol. 7, 37\u201361 (2020).","journal-title":"Annu. Rev. Virol."},{"key":"54666_CR31","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s41591-021-01403-9","volume":"27","author":"RM Dedrick","year":"2021","unstructured":"Dedrick, R. M. et al. Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection. Nat. Med. 27, 1357\u20131361 (2021).","journal-title":"Nat. Med."},{"key":"54666_CR32","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/cid\/ciab535","volume":"73","author":"DC Nguyen","year":"2021","unstructured":"Nguyen, D. C. et al. One-two punch\u201d: synergistic ss-lactam combinations for Mycobacterium abscessus and target redundancy in the inhibition of peptidoglycan synthesis enzymes. Clin. Infect. Dis. 73, 1532\u20131536 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"54666_CR33","doi-asserted-by":"crossref","unstructured":"Kaushik, A. et al. In vitro activity of the new beta-lactamase inhibitors relebactam and vaborbactam in combination with beta-lactams against Mycobacterium abscessus complex clinical isolates. Antimicrob. Agents Chemother. 63, e02623-18 (2019).","DOI":"10.1128\/AAC.02623-18"},{"key":"54666_CR34","doi-asserted-by":"crossref","unstructured":"Story-Roller, E., Maggioncalda, E. C. & Lamichhane, G. Synergistic efficacy of beta-lactam combinations against Mycobacterium abscessus pulmonary infection in mice. Antimicrob. Agents Chemother. 63, e00614-19 (2019).","DOI":"10.1128\/AAC.00614-19"},{"key":"54666_CR35","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00341-23","volume":"11","author":"J Luo","year":"2023","unstructured":"Luo, J. et al. Synergistic antibacterial effect of phage pB3074 in combination with antibiotics targeting cell wall against multidrug-resistant Acinetobacter baumannii in vitro and ex vivo. Microbiol. Spectr. 11, e0034123 (2023).","journal-title":"Microbiol. Spectr."},{"key":"54666_CR36","doi-asserted-by":"crossref","unstructured":"Save, J., Que, Y. A., Entenza, J. & Resch G. Subtherapeutic doses of vancomycin synergize with bacteriophages for treatment of experimental methicillin-resistant Staphylococcus aureus infective endocarditis. Viruses 14, 1792 (2022).","DOI":"10.3390\/v14081792"},{"key":"54666_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104045","volume":"80","author":"FL Gordillo Altamirano","year":"2022","unstructured":"Gordillo Altamirano, F. L. et al. Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study. EBioMedicine 80, 104045 (2022).","journal-title":"EBioMedicine"},{"key":"54666_CR38","doi-asserted-by":"crossref","unstructured":"Hendrix, C., McCrary, M., Hou, R. & Abate, G. Diagnosis and management of pulmonary NTM with a focus on Mycobacterium avium complex and Mycobacterium abscessus: challenges and prospects. Microorganisms 11, 47 (2022).","DOI":"10.3390\/microorganisms11010047"},{"key":"54666_CR39","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02924-23","volume":"15","author":"AA Schmalstig","year":"2024","unstructured":"Schmalstig, A. A. et al. Bacteriophage infection and killing of intracellular Mycobacterium abscessus. mBio 15, e0292423 (2024).","journal-title":"mBio"},{"key":"54666_CR40","doi-asserted-by":"crossref","unstructured":"Johansen, M. D. et al. Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus. Dis. Model Mech. 14, dmm049159 (2021).","DOI":"10.1242\/dmm.049159"},{"key":"54666_CR41","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s42003-024-06006-x","volume":"7","author":"F Yang","year":"2024","unstructured":"Yang, F. et al. Bacteriophage therapy for the treatment of Mycobacterium tuberculosis infections in humanized mice. Commun. Biol. 7, 294 (2024).","journal-title":"Commun. Biol."},{"key":"54666_CR42","doi-asserted-by":"crossref","unstructured":"Clary, G. et al. Mycobacterium abscessus smooth and rough morphotypes form antimicrobial-tolerant biofilm phenotypes but are killed by acetic acid. Antimicrob. Agents Chemother. 62, e01782-17 (2018).","DOI":"10.1128\/AAC.01782-17"},{"key":"54666_CR43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.virol.2012.09.026","volume":"434","author":"D Jacobs-Sera","year":"2012","unstructured":"Jacobs-Sera, D. et al. On the nature of mycobacteriophage diversity and host preference. Virology 434, 187\u2013201 (2012).","journal-title":"Virology"},{"key":"54666_CR44","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00174-24","volume":"68","author":"L Chen","year":"2024","unstructured":"Chen, L. et al. In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus. Antimicrob. Agents Chemother. 68, e0017424 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"54666_CR45","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/mmi.13946","volume":"108","author":"CC Ko","year":"2018","unstructured":"Ko, C. C. & Hatfull, G. F. Mycobacteriophage Fruitloop gp52 inactivates Wag31 (DivIVA) to prevent heterotypic superinfection. Mol. Microbiol. 108, 443\u2013460 (2018).","journal-title":"Mol. Microbiol."},{"key":"54666_CR46","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1128\/JB.01801-14","volume":"196","author":"LM Oldfield","year":"2014","unstructured":"Oldfield, L. M. & Hatfull, G. F. Mutational analysis of the mycobacteriophage BPs promoter PR reveals context-dependent sequences for mycobacterial gene expression. J. Bacteriol. 196, 3589\u20133597 (2014).","journal-title":"J. Bacteriol."},{"key":"54666_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02483-z","volume":"22","author":"RR Wick","year":"2021","unstructured":"Wick, R. R. et al. Trycycler: consensus long-read assemblies for bacterial genomes. Genome Biol. 22, 266 (2021).","journal-title":"Genome Biol."},{"key":"54666_CR48","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1093\/bioinformatics\/btt515","volume":"29","author":"D Gordon","year":"2013","unstructured":"Gordon, D. & Green, P. Consed: a graphical editor for next-generation sequencing. Bioinformatics 29, 2936\u20132937 (2013).","journal-title":"Bioinformatics"},{"key":"54666_CR49","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1093\/nar\/gkac273","volume":"50","author":"CH Gauthier","year":"2022","unstructured":"Gauthier, C. H. et al. DEPhT: a novel approach for efficient prophage discovery and precise extraction. Nucleic Acids Res. 50, e75 (2022).","journal-title":"Nucleic Acids Res."},{"key":"54666_CR50","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/s41564-021-00963-3","volume":"6","author":"C Ruis","year":"2021","unstructured":"Ruis, C. et al. Dissemination of Mycobacterium abscessus via global transmission networks. Nat. Microbiol. 6, 1279\u20131288 (2021).","journal-title":"Nat. Microbiol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54666-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54666-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54666-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T18:03:21Z","timestamp":1732817001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54666-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54666"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54666-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10360"}}